Table 2.
Baseline clinical characteristics
| Value | |
|---|---|
| Age, years, mean (SD) |
57 (13) |
| Male, n (%) |
33 (92%) |
| Ethnicity, n (%) |
15 (42%) European |
| 7 (19%) Māori | |
| 9 (25%) Pacific | |
| 5 (14%) Asian | |
| BMI, (kg/m2), mean (SD) |
34 (8) |
| Cardiovascular disease, n (%) |
16 (44%) |
| Type 2 diabetes, n (%) |
7 (19%) |
| Diuretic use, n (%) |
9 (25%) |
| Urate-lowering therapy use, n (%) |
34 (94%) |
| Colchicine use, n (%) |
23 (64%) |
| Prednisone use, n (%) |
10 (28%) |
| NSAID use, n (%) |
22 (61%) |
| Serum urate, mmol/l, mean (SD) |
0.39 (0.13) |
| Disease duration, years, mean (SD) |
15 (11) |
| Age at first episode, years, mean (SD) |
42 (19) |
| Self-reported flares in preceding 2 months, mean (SD) |
3.9 (10.8) |
| Days off work in last two months, mean (SD) |
0.3 (1.5) |
| In paid employment, n (%) |
17 (47%) |
| Aspirate proven, n (%) |
11 (31%) |
| Foot tophus count, mean (SD) |
1.3 (1.8) |
| Total tophus count, mean (SD) |
4.5 (4.1) |
| Any subcutaneous tophus, n (%) | 26 (72%) |